Losartan, the angiotensin-II type-1 receptor antagonist, appears more efficacious than the beta-blocker atenolol among hypertensive diabetics with left ventricular hypertrophy.
"The general message to the practicing physician is that hypertensive diabetic patients with LVH benefit more from losartan than atenolol," declares Dr Lars Hjalmar Lindholm, Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden. He is lead author of the European and North American collaborators in this study as part of the ongoing Losartan Intervention For Endpoint reduction (LIFE) study.
Diabetes mellitus doubles the risk of cardiovascular disease, even in patients with hypertension who are already at high risk because of their high blood pressure. A combination of hypertension and diabetes accounts for a large proportion of cardiovascular morbidity and mortality, the clinicians point out.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!